Evidence map›Paper›PMID 21697342›Full record

ArticleClinical and vaccine immunology : CVI2011

Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.

Ann Percival, Peter Thorkildson, Thomas R Kozel

Open access · diamondAbstract readEvaluation Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Cryptococcal meningitis.Nature reviews. Disease primers · 2023
    Review
  5. Cryptococcus neoformans, a global threat to human health.Infectious diseases of poverty · 2023
    Review
  6. Immunologic Diagnosis of Endemic Mycoses.Journal of fungi (Basel, Switzerland) · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Tropical medicine and infectious disease · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ann PercivalDepartment of Microbiology and Immunology, University of Nevada School of Medicine, Reno, NV 89557, USA.
Peter Thorkildson
Thomas R Kozel
University of Nevada, Reno · US

Funding

Cryptococcal polysaccharide-phagocytosis inhibitionR01AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1985 to 2009
$1.9M
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITIONR37AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1995 to 2004
$1.5M
NIAID NIH HHS AI-014209NIAID NIH HHS R01 AI014209NIAID NIH HHS R37 AI014209
6 · The paper itself

Abstract

Immunoassay for detection of glucuronoxylomannan (GXM), the major capsular polysaccharide of Cryptococcus neoformans, is an important tool for diagnosis of cryptococcosis. However, immunoassays that are based solely or in part on detection with polyclonal antibodies may show serotype bias in detection of GXM, particularly limited sensitivity for serotype C. In this study, we describe detection of GXM in an antigen capture sandwich enzyme-linked immunosorbent assay (ELISA) that used a cocktail of two monoclonal antibodies (MAbs). MAb F12D2 was previously produced by immunization with GXM that had been treated to remove O-acetyl groups, a major source of serotype specificity. MAb F12D2 has a high degree of reactivity with GXM of serotypes A, B, C, and D, but the reactivity with serotype D was less than was found with other MAbs. MAb 339 is highly reactive with GXM of serotypes A and D. Use of a combination of the two MAbs produced an immunoassay that had the best properties of both MAbs, including good reactivity with serotype C, which is an emerging threat in sub-Saharan Africa. These results suggest that next-generation immunoassays for diagnosis of cryptococcosis may be formulated by (i) use of immunization and hybridoma screening strategies that are designed to prospectively meet the needs of immunoassay performance and (ii) careful selection of MAbs that span the expected polysaccharide serotypes in the subject patient population.

Indexed as

Antibodies, MonoclonalAntigens, FungalCryptococcosisCryptococcus neoformansEnzyme-Linked Immunosorbent AssayEpitopesHumansMycological Typing TechniquesPolysaccharidesSensitivity and SpecificitySerotypingAntibodies, MonoclonalAntigens, FungalEpitopesglucuronoxylomannanPolysaccharides

Identifiers

PMID21697342
PMCPMC3147348
OpenAlexW2129559460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.